Celltrion announced Friday a monumental achievement for Zymfentra, its groundbreaking subcutaneous formulation of infliximab, reporting record-breaking prescription volumes during the first quarter of this year.
This impressive growth saw prescription volume skyrocket by an astonishing 185 percent year-on-year, surpassing the entirety of last year’s first-half results. This significant surge underscores Zymfentra’s robust market penetration and a clear upward trajectory in the competitive biopharmaceutical landscape.
The remarkable success is primarily attributed to the meticulous “3P strategy” implemented by Celltrion’s US subsidiary since Zymfentra’s market launch. This comprehensive approach strategically focuses on three core pillars: healthcare **providers**, health insurance **payers**, and ultimately, **patients**.
Engaging healthcare **providers**, particularly the prescribing physicians, remains a paramount priority. Following Zymfentra’s introduction, Celltrion executives, including CEO Seo Jung-jin, conducted extensive tours across the US. Their proactive efforts involved direct meetings with key medical professionals to personally introduce the innovative product and highlight its benefits.
Critical to Zymfentra’s widespread adoption has been the successful securing of comprehensive reimbursement coverage. This was achieved through sustained, close communication and strategic negotiations with a multitude of private insurers and prominent pharmacy benefit managers (PBMs).
Operating within the unique US pharmaceutical market, characterized by higher drug costs, necessitates robust reimbursement mechanisms for product viability. Celltrion’s US subsidiary has excelled in this area, successfully negotiating with major PBMs and diverse insurance providers. These efforts have culminated in securing coverage for over 90 percent of the total US insurance market, ensuring broad patient access to Zymfentra.
Beyond direct engagement and reimbursement, a multi-channel marketing strategy has significantly fueled Zymfentra’s growth. The company initiated extensive media campaigns across various platforms, including prominent TV advertisements, targeted YouTube content, and engaging social media outreach. Additionally, on-site in-hospital campaigns have been instrumental in directly informing and supporting patients at the point of care.
The positive momentum for Zymfentra is strongly projected to continue throughout the second half of the year. This sustained growth is anticipated due to established strong prescription infrastructure, continuously increasing visibility among both patients and medical personnel, and the consistent upward trend observed since its initial launch.
Complementing Zymfentra’s success, other high-profit Celltrion products such as Steqeyma, Avtozma, and Stoboclo-Osenvelt have also achieved significant milestones within the US market. These products have successfully secured substantial market shares and crucial reimbursement coverage, further solidifying Celltrion’s presence.
An official from Celltrion remarked, “Zymfentra is consistently setting new records each quarter. This outstanding performance is a testament to the effectiveness and precision of our carefully tailored sales and market access strategies specifically designed for the US pharmaceutical landscape.”
stlee0329
